A Phase 3 interventional study of clopidogrel (SR25990) and ticlopidine in Stable Angina and Myocardial Infarction, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-07-26.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing clopidogrel in Angina, Stable — none open to participants now, none under way, none of them phase 3. Clopidogrel · Angina, Stable.
Among the 10 studies testing clopidogrel in Angina, Stable, this one has the largest enrollment, is one of 3 that started in 2008, is one of 4 in phase 3, and was the 4th registered.
344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.
Browse Angina, Stable studies →None of the 10 studies testing clopidogrel in Angina, Stable is open now. The open studies under Angina, Stable, anywhere →
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 39 Angina, Stable studies recruiting now, 33 (85%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,003 is above the median of 150 across 231 interventional studies indexed under Angina, Stable.
Median enrollment 281 across the 10 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Angina, Stable — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing clopidogrel in Angina, Stable, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
Secondary objectives:
The study consisted of two periods:
All patients should receive aspirin (81-100 mg once daily) as a background therapy during investigational product administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stable Angina / Old Myocardial Infarction patients who met all of the following criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Patients received: * clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose, * ticlopidine matching placebo twice daily.
Drug: clopidogrel (SR25990) · Drug: Placebo
Patients received: * ticlopidine 100 mg twice daily, * clopidogrel matching placebo once daily.
Drug: ticlopidine · Drug: Placebo
Form: tablets Route: oral
Form: tablets Route: oral
Form: tablets Route: oral
Time from randomization to first safety events of interest
Safety events of interest were: * Clinically significant bleeding, * Leukopenia, neutropenia or thrombocytopenia occurring as adverse drug reaction, * Elevated liver function values occurring as adverse drug reaction, * Permanent investigational product discontinuation due to skin disorders, gastrointestinal disorders, bleeding, hepatic disorders, or significant decreases in such tests as leukocytes, neutrophils or platelets occurring as adverse drug reaction.
Time frame: 12 Weeks (duble blind treatment period)
Time from randomization to first Major Adverse Cardiac Events (MACE)
MACE included: * All- cause mortality, * Acute myocardial infarction, * Revascularization (excluding revascularization related to the planned PCI), * Stent thrombosis
Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)
Time from randomization to first bleeding events
Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)
Time from randomization to first Adverse Events / Adverse Drug Reactions
Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)
Time from randomization to first Major Adverse Cardiac and Cerebrovascular Events (MACCE)
MACCE included: * All- cause mortality, * Acute myocardial infarction, * Revascularization (excluding revascularization related to the planned PCI), * Stent thrombosis, * Ischemic stroke.
Time frame: 12 Weeks (double-blind treatment period) , 52 weeks (double-blind + open label treatment period)
The record gives a start of Dec 2008, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel